Chang-hua, Taiwan
Chang-hua, Taiwan

Time filter

Source Type

The stereoselective arylation of hydroxy protected 1,6-anhydro-β-d-glucose with arylalanes to provide β-C-arylglucosides is reported. Modification of triarylalanes, Ar3Al, with strong Brønsted acids (HX) or AlCl3 produced more reactive arylating agents, Ar2AlX, while the incorporation of alkyl dummy ligands into the arylating agents was also viable. Me3Al and i-Bu2AlH were found useful in the in situ blocking of the C3-hydroxyl group of 2,4-di-O-TBDPS protected 1,6-anhydroglucose. The utility of the method was demonstrated by the synthesis of the SGLT2 inhibitor, canagliflozin. © 2015 American Chemical Society.


News Article | November 23, 2016
Site: www.prnewswire.co.uk

Global Gemcitabine Market 2016 Research Report initially provides a basic overview of the industry that covers definition, applications and manufacturing technology, post which the report explores into the international players in the market. Complete report on Gemcitabine market spread across 107 pages providing 06 company profiles and 105 tables and figures is available at http://www.reportsnreports.com/reports/759063-global-gemcitabine-market-research-report-2016.html . Market Segment by Regions, this report splits Global into several key Region, with production, consumption, revenue, market share and growth rate of Gemcitabine in these regions, from 2011 to 2021 (forecast), like North America, China, Europe, Japan, India, Southeast Asia split by product type, with production, revenue, price, market share and growth rate of each type Split by application, this report focuses on consumption, market share and growth rate of Gemcitabine in each application. This report studies Gemcitabine in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with sales, price, revenue and market share for each manufacturer, covering Allergan, Sanofi, Pfizer, The Medicines Company, Theravance Biopharma and Basilea Pharmaceutica. Order a copy at http://www.reportsnreports.com/purchase.aspx?name=759063 . Some key points from list of tables and figures: Table 2015 Global Gemcitabine Revenue Share by Manufacturers Table 2016 Global Gemcitabine Revenue Share by Manufacturers Table Global Market Gemcitabine Average Price of Key Manufacturers (2015 and 2016) Figure Global Market Gemcitabine Average Price of Key Manufacturers in 2015 Table Manufacturers Gemcitabine Manufacturing Base Distribution and Sales Area Table Manufacturers Gemcitabine Product Type Figure Gemcitabine Market Share of Top 3 Manufacturers Figure Gemcitabine Market Share of Top 5 Manufacturers Table Global Gemcitabine Production by Regions (2011-2016) Figure Global Gemcitabine Production and Market Share by Regions (2011-2016) Figure Global Gemcitabine Production Market Share by Regions (2011-2016) Figure 2015 Global Gemcitabine Production Market Share by Regions Table Global Gemcitabine Revenue by Regions (2011-2016) Table Global Gemcitabine Revenue Market Share by Regions (2011-2016) Table 2015 Global Gemcitabine Revenue Market Share by Regions Table Global Gemcitabine Production, Revenue, Price and Gross Margin (2011-2016) Table North America Gemcitabine Production, Revenue, Price and Gross Margin (2011-2016) Similar research titled "United States Gemcitabine Hydrochloride Industry 2016 Market Research Report" is spread across 139 pages and profiles 14 companies that provide a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Gemcitabine Hydrochloride market analysis is provided for the United States markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and Bill of Materials cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. The report focuses on United States major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and downstream demand analysis is also carried out. The Gemcitabine Hydrochloride industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Few key manufacturers included in this report are Afine Chemicals, Arch Pharmalabs, Eli Lilly, Fresenius Kabi, Intas Pharmaceuticals, Jari Pharmaceutical, Jiangsu Hansoh, Ningbo Team, ScinoPharm Taiwan, Sun Pharmaceutical, Sunray Pharmaceutical, Tecoland, Teva Group and Zhejiang Hisun. 2016 Market Research Report on Global Internet of Things Industry is available at http://www.reportsnreports.com/reports/518534-united-states-gemcitabine-hydrochloride-industry-2016-market-research-report.html . Explore more reports on Pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ . ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more. Connect With Us on:


News Article | February 15, 2017
Site: www.prnewswire.com

TAINAN, Taiwan, Feb. 14, 2017 /PRNewswire/ -- ScinoPharm Taiwan, Ltd (TWSE: 1789), an active pharmaceutical ingredient (API) and formulation specialty company, announced unaudited financial results for its fiscal year 2016. The consolidated revenue was NT$4.031 billion (US$125 million),...


News Article | February 15, 2017
Site: en.prnasia.com

TAINAN, Taiwan, Feb. 15, 2017 /PRNewswire/ -- ScinoPharm Taiwan, Ltd (TWSE: 1789), an active pharmaceutical ingredient (API) and formulation specialty company, announced unaudited financial results for its fiscal year 2016. The consolidated revenue was NT$4.031 billion (US$125 million), after-tax net profits were NT$659 million (US$20.4 million). The after-tax earnings per share was NT$0.87 (US$0.027). In 2016, overall revenue increased by 2% compared to 2015 primarily as a result of the sales boost of generic APIs, including an increased market share of Gemcitabine combined with more flexible strategies, increased shipments of Paclitaxel, as well as greater customer needs of Entecavir (HBV) and Riluzole (ALS) in anticipation for commercial launch. In terms of contract research services (CRO), several customers have achieved favorable clinical results in their Phase III trials, suggesting an increased shipment volumes and revenues. Meanwhile, revenue from contract manufacturing services (CMO) suffered a sharp reduction due to lower order volume of anti-depressants and anti-obesity drugs, but the overall performance of 2016 has been promising. Increased profit is evident in an overall gross profit margin of 45%; this is a result of a favorable blend of products and clients, especially with increased sales volume of higher profit oncology products and CRO projects. The strategic entry of oncology API Gemcitabine also contributed strongly in the company's gross margin increase. ScinoPharm also demonstrated profitability improvement by tighter cost control, process optimization, and enhanced management efficiency. ScinoPharm continues to pursue strategic alliances in order to enhance its position as a developer and manufacturer of innovative products with high added value. Currently, two ANDA submissions have been filed: an oncology injectable drug jointly developed with U.S.-based SAGENT Pharmaceuticals, and ScinoPharm-developed Fondaparinux. Product partnerships based on co-development and profit-sharing models have been established for eleven products. Furthermore, ScinoPharm is currently negotiating with major international companies for exclusive distribution rights in Europe and the U.S for the drug products indicated for cancer, multiple sclerosis, osteoporosis, diabetes mellitus, etc. To this end, investments were made to enable a GMP-compliant manufacturing plant for injectable products. The injectable plant is being positioned to prepare its first registration batch this year, file ANDA submission by the end of 2018, and expect a USFDA on-site inspection in 2019. The Changshu site in Jiangsu, China, initiated full-scale operations, contributing to ScinoPharm's overall revenues. In efforts to expand the existing CRAM business operations, the company is focusing on mid- to late-phase projects. The current portfolio includes agents in the indications of oncology, anti-hypertension, diabetes, and other therapeutics. The Changshu site is also seeking large-volume generic APIs and intermediates to increase production utilization and is exploring partnerships with generic formulation firms to maximize market share in China via joint development and registration. Oncology products continue to be the mainstay of the company's portfolio. The three primary products in the last year include Paclitaxel for ovarian, lung, and breast cancer, Irinotecan for colorectal cancer, and Gemcitabine for small cell lung and breast cancer. These three products retained ScinoPharm's market share dominance worldwide, which reaffirms the company position as a global leader in oncology product supply. ScinoPharm's regulatory presence in oncology is demonstrated and strengthened by the number of completed drug master files (DMF): The Company has applied for 733 DMFs worldwide, including 55 in the US. Of the 55 US DMFs, 32 are for oncology products. This is an unparalleled number of total DMFs among the independent global providers of APIs and proof of the company's persistent efforts in oncology products. To date, ScinoPharm has developed 72 generic APIs, including 25 marketed products. Numerous others are awaiting the subsequent expiration of active patents. In 2017, ScinoPharm anticipates launching 2 APIs for generic, 1 API for CMO project, and 1 co-developed generic injectable drug, primarily in the US and European markets. These drugs are for the indications of polyuria, benign prostatic hyperplasia, infections, and oncology. ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With research and manufacturing facilities in both Taiwan and mainland China, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities for brand companies as well as APIs for the generic industry. The Company also is aggressively pursuing a vertically integrated, one-stop-shopping service for drug product customers by expanding into the field of sterile oncology injectable formulations. For more information, please visit the Company's website at http://www.scinopharm.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/scinopharm-reports-financial-performance-for-2016-300406864.html


DEERFIELD, Ill. & TAINAN, Taiwan--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) and ScinoPharm Taiwan, Ltd. (TWSE: 1789) today announced a strategic partnership to develop, manufacture and commercialize five injectable drugs used in a range of cancer treatments, including lung cancer, multiple myeloma and breast cancer, as well as medication to treat nausea and vomiting, common side effects of chemotherapy. The arrangement also provides Baxter the option to partner with ScinoPharm—one of the world’s leading active pharmaceutical ingredient (API) manufacturers—on as many as 15 additional injectable molecules. Under the terms of the partnership, Baxter and ScinoPharm will collaborate on product development and manufacturing. Baxter will hold commercialization rights, with products included in the arrangement expected to launch beginning in 2020. “ Combining Baxter’s differentiated manufacturing expertise and global commercialization capabilities with ScinoPharm’s recognized API experience enables Baxter to increase patient access to difficult-to-manufacture, high-quality oncolytic medicines,” said Robert Felicelli, president, Pharmaceuticals, Baxter. “ The ScinoPharm collaboration will further expand Baxter’s presence in generic injectables, which will continue to be enhanced through our recently executed agreement to acquire Claris Injectables Limited.” Current branded sales of the initial five products included in this partnership total more than $4 billion annually. These products will join Baxter’s existing portfolio of generic injectable medications, which includes difficult-to-manufacture oncology drugs and a broad portfolio of standard-dose, ready-to-use premixed injectable products such as anti-infectives, analgesics and critical care medicines. ScinoPharm has a 17-year history of manufacturing APIs for the global pharmaceutical industry with a high level of quality and safety. Under the arrangement, ScinoPharm will provide APIs for the initial five generic injectables, and Baxter and ScinoPharm will share manufacturing responsibilities, with the majority of the molecules to be manufactured at Baxter’s state-of-the-art facility in Halle, Germany, one of the most advanced facilities in the world for manufacturing oncology drugs. “ We are very excited to partner with Baxter. We bring complementary strengths to this arrangement that will ultimately lead to more injectable oncology products on the market,” said ScinoPharm CEO Dr. Yung Fa Chen. “ This strategic partnership will boost our expansion in the formulation business, increase market coverage of our products and eventually fuel our further operating performance.” ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With research and manufacturing facilities in both Taiwan and China, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities for brand companies as well as APIs for the generic industry. The Company also is aggressively pursuing a vertically integrated, one-stop-shopping service for drug product customers by expanding into the field of sterile oncological injectable formulations. Baxter International Inc. provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care. This release includes forward-looking statements concerning the entry by Baxter and ScinoPharm into a joint development agreement, including expectations regarding the number of molecules to be developed under the partnership agreement and the value of the co-developed molecules. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the ability of Baxter and ScinoPharm to develop, manufacture and commercialize new molecules in accordance with the terms of the agreement; continued strength in the financial position, including cash flows, of Baxter and ScinoPharm; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; and other risks identified in Baxter’s most recent filing on Form 10-K and other SEC filings, all of which are available on its website. Baxter does not undertake to update its forward-looking statements. This press release contains forward-looking statements. These forward-looking statements are based on current information and expectations, and are subject to risks and uncertainties, including market conditions and other factors outside of ScinoPharm’s control. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. ScinoPharm undertakes no obligation to publicly update any forward-looking statement contained in this release, whether as a result of new information, future developments or otherwise, except as may be required by law.


Gopula B.,National Taiwan Normal University | Tsai Y.-F.,National Taiwan Normal University | Kuo T.-S.,National Taiwan Normal University | Wu P.-Y.,ScinoPharm Taiwan | And 2 more authors.
Organic Letters | Year: 2015

The asymmetric conjugate addition of arylboronic acids to substituted and unsubstituted β-pyrazol-1-yl (E)-tert-butyl acrylates 4 catalyzed by 5 mol % of the Rh(I)/diene 2a catalyst provided the corresponding addition products in 44-98% yield and 91->99.5% ee. The method was applied to the formal synthesis of (3S)-3-aryl-3-(pyrazol-1-yl)propanoic acid 1b with agonistic activity toward the human GPR40 G-protein coupled receptor. © 2015 American Chemical Society.


Huang K.-C.,National Taiwan Normal University | Gopula B.,National Taiwan Normal University | Kuo T.-S.,National Taiwan Normal University | Chiang C.-W.,National Taiwan Normal University | And 3 more authors.
Organic Letters | Year: 2013

An efficient enantioselective addition of an array of arylboronic acids to various β-nitrostyrenes catalyzed by a novel and reactive rhodium-diene catalyst (S/C up to 1000) was developed, providing β,β- diarylnitroethanes in good to high yields (62-99%) with excellent enantioselectivities (85-97% ee). The method was extended to 2-heteroarylnitroolefins and 2-alkylnitroolefins similarly providing the desired products with high enantioselectivities and yields. The usefulness of this method was demonstrated in the formal synthesis of the enantiomer of the dopamine receptor agonist and antagonist, SKF 38393. © 2013 American Chemical Society.


Gopula B.,National Taiwan Normal University | Chiang C.-W.,National Taiwan Normal University | Lee W.-Z.,National Taiwan Normal University | Kuo T.-S.,National Taiwan Normal University | And 3 more authors.
Organic Letters | Year: 2014

For the first time, simple N-tosyl aryl aldimines, prepared from the condensation of tosyl amide and aromatic aldehydes, can be used as substrates in the rhodium catalyzed 1,2- addition reaction using alkenylboron nucleophiles. In the presence of 1.5 mol % of [RhCl(1e)]2, enantioselective addition of various potassium alkenyltrifluoroborates to aryl aldimines furnished the corresponding chiral allylic amines in 73-96% yield and 72->99.5% ee. Notably, this method efficiently provides the di-, tri-, and tetrasubstituted allylic N-tosyl amines with high asymmetric induction.© 2013 American Chemical Society.


PubMed | ScinoPharm Taiwan, National Taiwan Normal University and Tamkang University
Type: Journal Article | Journal: Chemistry (Weinheim an der Bergstrasse, Germany) | Year: 2015

Chiral rhodium catalysts comprising 2,5-diaryl- substituted bicyclo[2.2.1]diene ligands L1-L10 were utilized in the enantioselective 1,4-addition reaction of arylboronic acids to N-substituted maleimides. In the presence of 2.5mol% of Rh(I) /L2, enantioenriched conjugate addition adducts were isolated in 72-99% yields with 86-98%ee. This protocol offers a convenient method to access a variety of 3-arylsuccinimides in a highly enantioselective manner. Maleimides with readily cleavable N-protecting groups were tolerated enabling the synthesis of useful synthetic intermediates. Pyrrolidine 4, a biologically active compound, and pyrrolidine 5, an ent-precursor to an HSD-1 inhibitor, were synthesized to demonstrate the utility of this method.


PubMed | ScinoPharm Taiwan
Type: Journal Article | Journal: The Journal of organic chemistry | Year: 2015

The -selective phenylation of benzyl and boronate protected 1,6-anhydroglucose and the direct phenylation of unprotected 1,6-anhydroglucose (10), pretreated with i-Bu2AlH, i-Bu3Al, Et3Al, Me3Al, or n-octyl3Al, with triphenylalane or aryl(chloro)alanes is reported. The utility of the unprotected version of the method is demonstrated by the synthesis of the SGLT2 inhibitor, canagliflozin (1a), from commercially available 10 in one C-C bond-forming step. This approach circumvents the need for conventional protecting groups, and therefore no formal protection and deprotection steps are required.

Loading ScinoPharm Taiwan collaborators
Loading ScinoPharm Taiwan collaborators